CD8+ Treg Cells Associated with Decreasing Disease Activity after Intravenous Methylprednisolone Pulse Therapy in Lupus Nephritis with Heavy Proteinuria
Author(s) -
YiGiien Tsai,
ChiaYing Lee,
TzeYi Lin,
ChingYuang Lin
Publication year - 2014
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0081344
Subject(s) - lupus nephritis , proteinuria , medicine , methylprednisolone , nephritis , systemic lupus erythematosus , immunology , cd8 , gastroenterology , disease , immune system , kidney
We focus on the role of CD8 + Treg cell in Intravenous methyl-prednisolone (IVMP) pulse therapy in forty patients with active Class III/IV childhood lupus nephritis (LN) with heavy proteinuria. IVMP therapy for five days. From peripheral blood mononuclear cells (PBMCs) and renal tissues, we saw IVMP therapy definitely restoring both CD4 + CD25 + FoxP3 + and CD8 + CD25 + Foxp3 + Treg cell number plus greater expression with intracellular IL-10 and granzyme B in CD8 + FoxP3 + Treg from PBMCs. IVMP-treated CD8 + CD25 + Treg cells directly suppressed CD4 + T proliferation and induced CD4 + CD45RO + apoptosis. Histologically, CD4 + FoxP3 + as well as CD8 + FoxP3 + Treg cells appeared in renal tissue of LN patients before IVMP by double immunohistochemical stain. CD8 + FoxP3 + Treg cells increased in 10 follow-up renal biopsy specimens after IVMP. Reverse correlation of serum anti-C1q antibody and FoxP3 + Treg cells in PBMNCs (r = −0.714, P<0.01). After IVMP, serum anti-C1q antibody decrease accompanied increase of CD4 + FoxP3 + Treg cells. CD8 + Treg cells reduced interferon-r response in PBMCs to major peptide autoepitopes from nucleosomes after IVMP therapy; siRNA of FoxP3 suppressed granzyme B expression while decreasing CD8 + CD25 + Treg-induced CD4 + CD45RO + apoptosis. Renal activity of LN by SLEDAI-2k in childhood LN was significantly higher than two weeks after IVMP (P<0.01). CD8 + FoxP3 + Treg cells return in post-IVMP therapy and exert crucial immune modulatory effect to control autoimmune response in LN. Trial Registration DMR97-IRB-259
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom